PL2905335T3 - Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo - Google Patents

Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo

Info

Publication number
PL2905335T3
PL2905335T3 PL13843070T PL13843070T PL2905335T3 PL 2905335 T3 PL2905335 T3 PL 2905335T3 PL 13843070 T PL13843070 T PL 13843070T PL 13843070 T PL13843070 T PL 13843070T PL 2905335 T3 PL2905335 T3 PL 2905335T3
Authority
PL
Poland
Prior art keywords
vivo
antibody
tumor activity
human dlk
dlk
Prior art date
Application number
PL13843070T
Other languages
English (en)
Inventor
Koji Nakamura
Hiroyuki Yanai
Toru Kanke
Naoya Tsurushita
Shankar Kumar
Original Assignee
Chiome Bioscience Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc. filed Critical Chiome Bioscience Inc.
Publication of PL2905335T3 publication Critical patent/PL2905335T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL13843070T 2012-10-03 2013-10-03 Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo PL2905335T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709282P 2012-10-03 2012-10-03
EP13843070.7A EP2905335B1 (en) 2012-10-03 2013-10-03 Anti-human dlk-1 antibody having anti-tumor activity in vivo
PCT/JP2013/077540 WO2014054820A1 (ja) 2012-10-03 2013-10-03 in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体

Publications (1)

Publication Number Publication Date
PL2905335T3 true PL2905335T3 (pl) 2018-06-29

Family

ID=50435137

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13843070T PL2905335T3 (pl) 2012-10-03 2013-10-03 Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo

Country Status (19)

Country Link
US (1) US9303086B2 (pl)
EP (1) EP2905335B1 (pl)
JP (1) JP6280040B2 (pl)
KR (1) KR102149565B1 (pl)
CN (1) CN104704119B (pl)
AU (1) AU2013325443B2 (pl)
CA (1) CA2886772C (pl)
CY (1) CY1120063T1 (pl)
DK (1) DK2905335T3 (pl)
ES (1) ES2665341T3 (pl)
HR (1) HRP20180685T1 (pl)
HU (1) HUE037274T2 (pl)
LT (1) LT2905335T (pl)
NO (1) NO2972360T3 (pl)
PL (1) PL2905335T3 (pl)
PT (1) PT2905335T (pl)
RS (1) RS57120B1 (pl)
SI (1) SI2905335T1 (pl)
WO (1) WO2014054820A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101619862B1 (ko) * 2014-09-30 2016-05-12 주식회사 녹십자 간접효소면역측정법을 이용하는 인간 Fc 포함 단백질의 역가 측정키트 및 이를 이용한 Fc 포함 단백질의 역가 측정방법
MX2019009427A (es) 2017-02-08 2019-10-07 Medimmune Ltd Conjugados de pirrolobenzodiazepinas y anticuerpos.
WO2019050362A2 (ko) 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
CN113660954A (zh) * 2019-04-01 2021-11-16 凯奥目生物科学株式会社 癌症治疗用药物
EP4226945A1 (en) 2020-10-05 2023-08-16 Chiome Bioscience, Inc Medicine for treating cancer
AU2022271741A1 (en) 2021-05-10 2023-11-23 Chiome Bioscience Inc. Purification method of antibody composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0605522B1 (en) * 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0673390B1 (en) 1992-12-11 2000-07-12 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Delta-like gene expressed in neuroendocrine tumors
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JP2001269174A (ja) 2000-03-24 2001-10-02 Kirin Brewery Co Ltd 骨髄異形成症候群（ｍｄｓ）の検出方法及びｍｄｓの治療剤
US20030185815A1 (en) 2001-04-03 2003-10-02 Muralidhara Padigaru Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US20040241170A1 (en) 2001-08-24 2004-12-02 Jensen Charlotte Harken Isolation of cells from neural cell populations using antibodies to fa1/dlk1
BRPI0308585B8 (pt) * 2002-03-13 2021-05-25 Biogen Idec Inc anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna
US20050221392A1 (en) 2002-03-21 2005-10-06 Charlotte Harken Jensen Detection and isolation of cell populations from muscle using antibodies to fa1/dlk1
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US20070224201A1 (en) 2002-10-02 2007-09-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005052156A1 (ja) 2003-11-28 2005-06-09 Kanagawa Academy Of Science And Technology 肝癌の検出方法及び肝癌診断薬並びに癌治療薬
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
JP5615169B2 (ja) 2008-03-17 2014-10-29 株式会社リブテック ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
RU2015102845A (ru) * 2010-02-23 2015-06-10 Санофи АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
SI2566517T1 (sl) * 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Protitelesa, ki vežejo CSF1R

Also Published As

Publication number Publication date
SI2905335T1 (en) 2018-04-30
EP2905335B1 (en) 2018-01-31
HUE037274T2 (hu) 2018-08-28
CA2886772A1 (en) 2014-04-10
NO2972360T3 (pl) 2018-08-04
US20140193432A1 (en) 2014-07-10
US9303086B2 (en) 2016-04-05
LT2905335T (lt) 2018-04-10
RS57120B1 (sr) 2018-06-29
CN104704119B (zh) 2017-09-05
KR102149565B1 (ko) 2020-08-28
JPWO2014054820A1 (ja) 2016-08-25
AU2013325443A1 (en) 2015-04-09
DK2905335T3 (en) 2018-03-12
CA2886772C (en) 2021-01-12
KR20150060761A (ko) 2015-06-03
HRP20180685T1 (hr) 2018-06-01
EP2905335A4 (en) 2016-05-18
JP6280040B2 (ja) 2018-02-14
CY1120063T1 (el) 2018-12-12
PT2905335T (pt) 2018-03-12
AU2013325443B2 (en) 2019-01-31
ES2665341T3 (es) 2018-04-25
WO2014054820A1 (ja) 2014-04-10
CN104704119A (zh) 2015-06-10
EP2905335A1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
EP2799452A4 (en) ANTIBODY AGAINST HUMAN TROP-2 WITH ANTITUMOUS EFFECT IN VIVO
EP2749572A4 (en) NEW ANTI-DDR1 ANTIBODY WITH ANTITUMORACTIVITY
EP2573120A4 (en) ANTIBODY AGAINST HUMAN TROP-2 WITH IN VIVO ANTITUMOR EFFECT
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
AP2014008102A0 (en) Anti-FcRn antibodies
EP2841082A4 (en) ANTIBODIES REGULATED BY PROTEASES
HRP20180685T1 (hr) Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo
TWI563004B (en) Anti-hxcr1 antibody
EP2720718A4 (en) ANTI-CD3 THERAPIES
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
GB201107656D0 (en) Short back and sides
HUP1100282A2 (en) Protein factor
GB201107773D0 (en) Travel playpen